Shares of REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) have received an average rating of "Moderate Buy" from the six analysts that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $28.3750.
RGNX has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of REGENXBIO from a "hold" rating to a "strong sell" rating in a research note on Saturday, August 9th. Royal Bank Of Canada lowered their target price on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research note on Friday, August 8th. Barclays lowered their target price on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a research note on Friday, August 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $34.00 target price on shares of REGENXBIO in a research note on Tuesday.
Check Out Our Latest Report on REGENXBIO
REGENXBIO Price Performance
Shares of NASDAQ RGNX traded up $0.90 during midday trading on Tuesday, reaching $9.01. 1,355,248 shares of the company traded hands, compared to its average volume of 680,725. REGENXBIO has a 52 week low of $5.03 and a 52 week high of $13.48. The stock has a 50-day moving average price of $8.52 and a 200 day moving average price of $8.07. The company has a market cap of $455.10 million, a price-to-earnings ratio of -2.62 and a beta of 1.11.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. The company had revenue of $21.36 million for the quarter, compared to the consensus estimate of $40.87 million. As a group, analysts expect that REGENXBIO will post -4.84 EPS for the current year.
Hedge Funds Weigh In On REGENXBIO
Several institutional investors and hedge funds have recently bought and sold shares of RGNX. Millennium Management LLC grew its stake in shares of REGENXBIO by 406.3% in the 4th quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock valued at $10,222,000 after buying an additional 1,061,187 shares in the last quarter. 22NW LP bought a new stake in shares of REGENXBIO in the 1st quarter valued at approximately $4,781,000. AQR Capital Management LLC grew its stake in shares of REGENXBIO by 2,247.7% in the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company's stock valued at $4,437,000 after buying an additional 594,161 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of REGENXBIO in the 4th quarter valued at approximately $3,865,000. Finally, Vanguard Group Inc. grew its stake in shares of REGENXBIO by 16.3% in the 1st quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company's stock valued at $24,832,000 after buying an additional 487,036 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
